STUDIES ON THE PREPARATION AND ISOMERIC COMPOSITION OF RE-186-PENTAVALENT AND RE-188-PENTAVALENT RHENIUM DIMERCAPTOSUCCINIC ACID COMPLEX

被引：65

作者：

SINGH, J ^{[1
]}

REGHEBI, K ^{[1
]}

LAZARUS, CR ^{[1
]}

CLARKE, SEM ^{[1
]}

CALLAHAN, AP ^{[1
]}

KNAPP, FF ^{[1
]}

BLOWER, PJ ^{[1
]}

机构：

[1] UNIV CANTERBURY,BIOL LAB,CANTERBURY CT2 7NJ,ENGLAND

来源：

NUCLEAR MEDICINE COMMUNICATIONS | 1993年 / 14卷 / 03期

关键词：

D O I：

10.1097/00006231-199303000-00009

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The preparative conditions for Re-186(V)DMSA and Re-188(V)DMSA (DMSA = meso-dimercaptosuccinic acid), beta-emitting radiopharmaceuticals that have been shown to localize in medullary thyroid carcinoma, require modification depending on the amount of carrier rhenium and the chemical form and medium in which the rhenium is supplied. Preparative conditions are described for use with carrier-free (ReO4-)-Re-188 in saline, and for use with (ReO4-)-Re-186 in saline, sodium hydroxide or nitric acid. Preparation of Re-186(V)DMSA (carrier present up to 2 mg per 2.5 ml reaction volume) requires a DMSA:SnCl2:Re ratio of 10:5:1 at 100-degrees-C for 30 min. Addition of excess nitric acid or hydrochloric acid up to a concentration of 155 mm does not reduce the yield from 100%. A commercial DMSA kit vial (e.g. Amerscan DMSA) can be used for preparation of Re-188(V)DMSA (carrier free) provided the required activity is in a volume of less than 1 ml per vial. A convenient method of concentrating the Re-188 generator eluate to the required volume is described.

引用

页码：197 / 203

页数：7

共 11 条

[1]

Ohta H., Endo K., Fujita T., Et al., Imaging of head and neck tumors with technetium-99m-(V)-DMSA, a new tumor seeking agent, Clin Nud Med, 10, pp. 855-860, (1985)

[2]

Watkinson J.C., Lazarus C.R., Mistry R., Shaheen O.H., Maisey M.N., Clarke S.E., Technetium-99-m-dimercapto- succinic acid uptake in patients with head and neck squamous carcinoma: Experience in imaging, J. Nucl Med, 30, pp. 174-180, (1989)

[3]

Ohta H., Yamamoto K., Endo K., Et al., A new imaging agent medullary carcinoma of the thyroid, J.Nucl Med, 25, pp. 323-325, (1984)

[4]

Clarke S., Lazarus C.R., Wraight P., Sampson C., Maisey M.N., Pentavalent [99m]DMSA, [13II]MIBG, and [99m]MDP - an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroi, J. Nucl Med, 29, pp. 33-38, (1988)

[5]

Ohta H., Endo K., Fujita T., Et al., Clinical evaluation of tumour imaging using99m(V)dimercaptosuccinic acid, a new tumour seeking agent, Nucl Med Commun, 9, pp. 105-116, (1988)

[6]

Bisunadan M.M., Blower P.J., Clarke S., Singh J., Went M.J., Synthesis and characterization of [186]rhenium(V) dimercaptosuccinic acid: A possible tumour radiotherapy agent, Appl Radiat Isot, 42, pp. 167-171, (1991)

[7]

Allen S.J., Blake G.M., McKeeney D.B., Lazarus C.R., Blower P.J., Singh J., Page C., Clarke S., A new radiopharma ceutical,186-V-DMSA, for therapy of medullary carcinoma of the thyroid, Eur J Nucl Med, 432, (1990)

[8]

Blower P.J., Singh J., Clarke S., The chemical identity of pentavalent technetium-99m-DMSA, J. Nucl Med, 32, pp. 845-849, (1991)

[9]

Blower P.J., Singh J., Clarke S., The chemical identity of pentavalent technetium-DMSA and editorial: Small coordination complexes in tumor imaging, J. Nucl Med, 33, (1992)

[10]

Callahan A.P., Rice D.E., Knapp F.F., Rhenium-188 for therapeutic applications from an alumina based tungsten- 188/rhenium-188 radionuclide generator, Nuccompact, 20, pp. 3-6, (1989)

← 1 2 →